English
Nederlands
Français
Deutsch
Italiano
Português
Русский
Español
ไทย
简体中文
हिन्दी
日本語
By Will Feuer
Novavax said the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended a full marketing authorization for the Nuvaxovid, the company’s Covid-19 vaccine.
The CHMP recommended the authorization of the vaccine for use as a primary series in people aged 12 and older, and as a booster in people aged 18 and older for the prevention of Covid-19 in the European Union.
Chief Executive John Jacobs said the CHMP opinion helps provide an approval pathway for an updated vaccine in time for the fall.
Write to Will Feuer at Will.Feuer@wsj.com
Read the full article here
Discussion about this post